Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.34 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.34 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.34 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771170 | 1.00 | CYSLTR2 (0.41) | CYSLTR2CYSLTR1PPARAPOLMPOLK | |
| SCHEMBL3763438 | 0.96 | CYSLTR2 (0.37) | CYSLTR2CYSLTR1PPARAPOLMPOLK | |
| SCHEMBL3659528 | 0.96 | CYSLTR2 (0.37) | CYSLTR2CYSLTR1PPARAPOLMPOLK | |
| SCHEMBL3660887 | 0.91 | CTSL (0.35) | CYSLTR2CYSLTR1CTSLCTSSCTSK | |
| SCHEMBL3769102 | 0.91 | CTSL (0.35) | CYSLTR2CYSLTR1CTSLCTSSCTSK | |
| SCHEMBL3660872 | 0.85 | PTPN1 (0.38) | PPARAPPARGPTGS2PTPN1 | |
| SCHEMBL3764580 | 0.85 | PTPN1 (0.38) | PPARAPPARGPTGS2PTPN1 | |
| SCHEMBL3659486 | 0.85 | CTSS (0.34) | CTSLCTSSCTSK | |
| SCHEMBL3768078 | 0.85 | CTSS (0.34) | CTSLCTSSCTSK | |
| SCHEMBL3662544 | 0.84 | L3MBTL1 (0.38) | PPARGPTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | CYSLTR2 2358/4885CYSLTR1 2654/4885PPARA 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.